Supplementary Online Content


eFigure 1. Algorithm Describing Protocol-Defined Recommendations for Clinical Management of Patients Randomized to Either the CCTA Screening or Control Groups
eFigure 2. Kaplan-Meier Event Survival Curves for the Composite Endpoint of Ischemic MACE (Coronary Artery Disease death, Non-Fatal Myocardial Infarction, and Hospitalization For Unstable Angina), All-Cause Death, and Cardiovascular Death
eTable 1. Success Rates for Reaching Aggressive Risk Factor Reduction Care Targets Among the 277 Qualifying CCTA Patients
eTable 2. Results of Analysis of the Primary Endpoint for the Randomized Groups (CCTA Vs No CCTA By Subgroups; the Same Results Are Shown in the eFigure)
eFigure 3. Results of Analysis of the Primary Endpoint for the Randomized Groups (CCTA Vs No CCTA By Subgroups; the Same Results Are Shown in eTable 2)

This supplementary material has been provided by the authors to give readers additional information about their work.
Supplemental Figures Legend

eFigure 1. Algorithm describing protocol-defined recommendations for clinical management of patients randomized to either the CCTA screening or control groups. +Stenosis severity was defined as follows: severely stenotic, ≥70% diameter stenosis in at least one major proximal or large coronary artery; moderately stenotic, 50%-69% stenosis in at least one major proximal or large coronary artery; mildly stenotic, 10%-49% stenosis in any coronary artery; normal, <10% stenosis and minimal or no evidence of plaque.

eFigure 2. Kaplan-Meier event survival curves for the composite endpoint of ischemic MACE (CAD death, non-fatal MI and hospitalization for unstable angina), all cause death and cardiovascular death.

   eFigure 2a. Curves by intention-to-treat analysis
   eFigure 2b. Curves by as-treated analysis
Enrollment

Control

Asymptomatic Screening

Creatinine ≥2.0 mg/dL (men)
≥1.8 mg/dL (women)
Heart rate not controlled to ≤60 bpm
Contrast allergy
Patient decision

Yes

No

CAC Score 0-10

CAC Score >10-100

CAC Score >100

No Significant ischemia

Stress Imaging Study

Significant Ischemia

Coronary Angiography and Revascularization as Needed

Aggressive Risk Factor Reduction Care Targets
1. HbA1C <6.0%
2. LDL chol <70 mg/dL
3. HDL chol >50 (women) >40 (men) mg/dL
4. TG<150 mg/dL
5. Systolic BP<120 mm Hg

Follow-up

Primary and Secondary Endpoints

Normal†

Mild stenosis†

Mod. Stenosis†

Severe Prox. Stenosis†

Full CCTA

© 2014 American Medical Association. All rights reserved.
KM Curve, Outcome: Ischemic MACE(CAD Death/Non–Fatal MI/Hosp. for Unstable Angina)

KM Curve, Outcome: Death (all cause)

KM Curve, Outcome: CV Death

© 2014 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>1-yr Risk Factors</th>
<th>Aggressive Group (n=277)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C &lt;6.0%, No. (%)</td>
<td>44 (15.9)</td>
</tr>
<tr>
<td>LDL chol &lt;70 mg/dL, No. (%)</td>
<td>126 (45.5)</td>
</tr>
<tr>
<td>HDL chol &gt;50 (women) &gt;40 (men) mg/dL, No. (%)</td>
<td>112 (40.4)</td>
</tr>
<tr>
<td>TG&lt;150 mg/dL, No. (%)</td>
<td>180 (65.0)</td>
</tr>
<tr>
<td>Systolic BP&lt;120 mm Hg, No. (%)</td>
<td>78 (28.2)</td>
</tr>
</tbody>
</table>
eTable 2. Results of analysis of the primary endpoint for the randomized groups (CCTA vs No CCTA by subgroups. The same results are shown in Forest plot form below.

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>N</th>
<th>MACE %</th>
<th>HR for MACE</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM Type 2</td>
<td>791</td>
<td>7.20%</td>
<td>0.75</td>
<td>(0.45, 1.27)</td>
<td>0.28</td>
</tr>
<tr>
<td>Hemoglobin A1c≥7</td>
<td>483</td>
<td>8.30%</td>
<td>0.74</td>
<td>(0.39, 1.39)</td>
<td>0.35</td>
</tr>
<tr>
<td>Insulin Use</td>
<td>386</td>
<td>7.30%</td>
<td>0.76</td>
<td>(0.36, 1.61)</td>
<td>0.47</td>
</tr>
<tr>
<td>Statin Use</td>
<td>668</td>
<td>7.30%</td>
<td>0.81</td>
<td>(0.46, 1.42)</td>
<td>0.47</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>567</td>
<td>7.60%</td>
<td>0.77</td>
<td>(0.42, 1.41)</td>
<td>0.39</td>
</tr>
<tr>
<td>Hypertension</td>
<td>595</td>
<td>8.40%</td>
<td>0.81</td>
<td>(0.46, 1.42)</td>
<td>0.46</td>
</tr>
<tr>
<td>FRS &lt;10%</td>
<td>349</td>
<td>7.16%</td>
<td>0.57</td>
<td>(0.25, 1.29)</td>
<td>0.18</td>
</tr>
<tr>
<td>FRS 10-20%</td>
<td>420</td>
<td>5.95%</td>
<td>1.55</td>
<td>(0.70, 3.45)</td>
<td>0.28</td>
</tr>
<tr>
<td>FRS &gt;20%</td>
<td>130</td>
<td>9.23%</td>
<td>0.37</td>
<td>(0.11, 1.22)</td>
<td>0.10</td>
</tr>
</tbody>
</table>

**Figure 3. Results of Analysis of the Primary Endpoint for the Randomized Groups (CCTA Vs No CCTA By Subgroups; the Same Results Are Shown in eTable 2)**